Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
The index, which outperformed the Dow Jones and the Nasdaq this month, gained 11 percent and rebounded from its 11 percent loss in December.
PacBio agreed to pay attorneys' fees to settle lawsuits brought against it by investors regarding Illumina's acquisition.
Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
PacBio's shares skyrocketed 76 percent in November on the news that Illumina plans to acquire the firm for $1.2 billion in cash.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.